Gilead Sciences and Sovaldi : the cost of a cure (A) / Benjamin Budish, Chase Lane, Richard Zaleski, James S. O'Rourke.
Gilead Sciences hepatitis C drug, Sovaldi, proved more effective than the competition and was priced in line with market conditions. However, extremely high cost and large patient population captured the attention of the media, the public, NGOs, and even the government. The controversy deepened when...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Ebook |
| Language: | English |
| Published: |
London :
SAGE Publications Ltd,
2017.
|
| Series: | SAGE Knowledge. Cases.
|
| Subjects: | |
| Online Access: | SAGE |
| Summary: | Gilead Sciences hepatitis C drug, Sovaldi, proved more effective than the competition and was priced in line with market conditions. However, extremely high cost and large patient population captured the attention of the media, the public, NGOs, and even the government. The controversy deepened when the company revealed the cost in developing countries would be roughly 1% of the cost in the U.S. |
|---|---|
| Item Description: | Originally published in Budish, B., Lane, C., Zaleski, R., & ORourke, J. S. (2014). Gilead Sciences and Sovaldi: The cost of a cure (A). 14-10 (A). Notre Dame, IN: The Eugene D. Fanning Center for Business Communication, Mendoza College of Business, University of Notre Dame. |
| Physical Description: | 1 online resource : illustrations. |
| ISBN: | 1526403110 9781526403117 |